LeonaBio マネジメント

マネジメント基準チェック /34

LeonaBioの CEO はMark Littonで、 Oct2021年に任命され、の在任期間は 4.58年です。の年間総報酬は$ 1.42Mで、 43.9%給与と56.1%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.64%を直接所有しており、その価値は$ 603.13K 。経営陣と取締役会の平均在任期間はそれぞれ2.7年と4.3年です。

主要情報

Mark Litton

最高経営責任者

US$1.4m

報酬総額

CEO給与比率	43.90%
CEO在任期間	4.6yrs
CEOの所有権	0.6%
経営陣の平均在職期間	2.7yrs
取締役会の平均在任期間	4.3yrs

経営陣の近況

Recent updates

分析記事 • Feb 16

Athira Alzheimer's drug trial gets monitoring panel nod to continue after efficacy analysis

Athira Pharma (NASDAQ:ATHA) said an independent data monitoring committee recommended to continue a phase 2/3 trial of fosgonimeton (ATH-1017) to treat patients with mild-to-moderate Alzheimer's disease (AD). The committee made the recommended after an interim efficacy and futility analysis of the study, dubbed LIFT-AD, the company added. In addition, the panel decided that, with the additional enrollment of fewer than 150 patients for a total enrollment of less than 300 people without background therapy (acetylcholinesterase inhibitors), the trial will be well powered for the main goal given the preliminary effect size seen, according to the company. The main goal of the trial is Global Statistical Test, a tool for measuring cognition and function. Athira noted that data from a phase 2 study called ACT-AD had showed a favorable safety profile and suggested positive effects on measures of cognition, function and neurodegeneration in patients taking fosgonimeton without background therapy. ATHA +2.49% to $3.29 premarket Oct. 17

Seeking Alpha • Aug 15

Athira Pharma GAAP EPS of -$0.65

Athira Pharma press release (NASDAQ:ATHA): Q2 GAAP EPS of -$0.65. Cash, cash equivalents and investments were $282.2 million as of June 30, 2022, compared with $319.7 million as of December 31, 2021.

分析記事 • Aug 09

We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Seeking Alpha • Jun 22

Athira Pharma: The Market Is Missing A Potential New Alzheimer's Drug

Athira Pharma has just read out first Phase 2 results in one of two Alzheimer’s trials. Its drug candidate ATH-1017 targets the HGF/MET pathway, a unique approach which has led to promising Phase 1 data. The readout shows efficacy in a subgroup, underlining validity of the proposed pathway and drug candidate ATH-1017, and I expected this would happen. The company's shares are falling severely on the primary endpoint miss. Simply stated, if the primary endpoint would have been cognition in the monotherapy group, then the results would have been seen as successful, which is why I believe there is potential to be a new Alzheimer's drug in the making here.

分析記事 • May 08

Companies Like Athira Pharma (NASDAQ:ATHA) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

分析記事 • Jan 11

We're Not Very Worried About Athira Pharma's (NASDAQ:ATHA) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Seeking Alpha • Jun 29

Athira Pharma: What, Exactly, Did The CEO Do?

CEO Leen Kawas is on leave because she is pending review for allegations of scientific misconduct. The science in question relates to Athira's core work in Alzheimer's. How strongly they are related will determine Athira's future.

分析記事 • May 24

We Think Athira Pharma (NASDAQ:ATHA) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

分析記事 • Feb 08

We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

分析記事 • Dec 18

Here's What Athira Pharma, Inc.'s (NASDAQ:ATHA) Shareholder Ownership Structure Looks Like

The big shareholder groups in Athira Pharma, Inc. ( NASDAQ:ATHA ) have power over the company. Institutions often own...

CEO報酬分析

LeonaBio の収益と比較して、Mark Litton の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2026	n/a	n/a	-US$129m
Dec 31 2025	US$1m	US$625k	-US$106m
Sep 30 2025	n/a	n/a	-US$38m
Jun 30 2025	n/a	n/a	-US$60m
Mar 31 2025	n/a	n/a	-US$80m
Dec 31 2024	US$3m	US$625k	-US$97m
Sep 30 2024	n/a	n/a	-US$109m
Jun 30 2024	n/a	n/a	-US$113m
Mar 31 2024	n/a	n/a	-US$116m
Dec 31 2023	US$2m	US$585k	-US$118m
Sep 30 2023	n/a	n/a	-US$121m
Jun 30 2023	n/a	n/a	-US$108m
Mar 31 2023	n/a	n/a	-US$102m
Dec 31 2022	US$4m	US$543k	-US$96m
Sep 30 2022	n/a	n/a	-US$82m
Jun 30 2022	n/a	n/a	-US$77m
Mar 31 2022	n/a	n/a	-US$67m
Dec 31 2021	US$3m	US$450k	-US$55m
Sep 30 2021	n/a	n/a	-US$46m
Jun 30 2021	n/a	n/a	-US$39m
Mar 31 2021	n/a	n/a	-US$27m
Dec 31 2020	n/a	n/a	-US$20m
Sep 30 2020	n/a	n/a	-US$13m
Jun 30 2020	n/a	n/a	-US$6m
Mar 31 2020	n/a	n/a	-US$6m
Dec 31 2019	US$204k	US$12k	-US$5m

報酬と市場: Markの総報酬 ($USD 1.42M ) は、 US市場 ($USD 638.05K ) の同規模の企業の平均を上回っています。

報酬と収益: Markの報酬は、過去 1 年間の会社の業績と一致しています。

CEO

Mark Litton (57 yo)

4.6yrs

在職期間

US$1,423,815

報酬

Dr. Mark J. Litton, Ph D., MBA, serves as Director at Lumen Bioscience, Inc. since October 2020. He served as Chief Operating Officer of LeonaBio, Inc. (formerly known as Athira Pharma, Inc.) since July 20...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Mark Litton	President	4.6yrs	US$1.42m	0.64% $ 603.1k
Mark Worthington	General Counsel	4.9yrs	US$731.48k	0.20% $ 185.0k
Javier San Martin	Chief Medical Officer	2.1yrs	US$810.14k	0.17% $ 160.0k
Robert Renninger	Chief Financial Officer	1.6yrs	データなし	0.17% $ 159.6k
Kevin Church	Chief Scientific Officer	3.3yrs	US$1.34m	0.27% $ 253.5k
Julie Rathbun	Head of Investor Relations	no data	データなし	データなし
Mark F. Kubik	Chief Business Officer	less than a year	データなし	データなし

2.7yrs

平均在職期間

58yo

平均年齢

経験豊富な経営陣: LONAの経営陣は経験豊富であると考えられます ( 2.7年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Mark Litton	President	4.6yrs	US$1.42m	0.64% $ 603.1k
Grant Pickering	Independent Director	4.3yrs	US$50.16k	0.027% $ 26.0k
Kelly Romano	Independent Chairwoman of the Board	5.4yrs	US$90.66k	0.086% $ 81.3k
Joseph Edelman	Independent Director	6yrs	US$49.16k	0% $ 0
Hans Moebius	Member of Scientific Advisory Board	3.9yrs	US$1.29m	データなし
Marwan Sabbagh	Member of Scientific Advisory Board	3.9yrs	データなし	データなし
Barbara Kosacz	Independent Director	5.2yrs	US$59.16k	0% $ 0
Pierre Tariot	Member of Scientific Advisory Board	3.9yrs	データなし	データなし
Michael A. Panzara	Independent Director	4.2yrs	US$59.16k	0% $ 0
James Johnson	Independent Director	5.8yrs	US$70.16k	0.0053% $ 5.0k
John Olichney	Member of Scientific Advisory Board	3.9yrs	データなし	データなし
Anton Porsteinsson	Member of Scientific Advisory Board	3.9yrs	データなし	データなし

4.3yrs

平均在職期間

63yo

平均年齢

経験豊富なボード: LONAの取締役会は経験豊富であると考えられます ( 4.3年の平均在任期間)。

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2026/05/22 08:45
終値	2026/05/21 00:00
収益	2026/03/31
年間収益	2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

LeonaBio, Inc. 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。7

アナリスト	機関
Esther Lannie Hong	Berenberg
Eric Schmidt	Cantor Fitzgerald & Co.
Jason Butler	Citizens JMP Securities, LLC

LeonaBio マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Insufficient new directors

LeonaBio, Inc., Annual General Meeting, Jun 22, 2026

Leonabio, Inc. Announces the Appointment of Mark F. Kubik as Chief Business Officer

Insufficient new directors

Athira Pharma, Inc., Annual General Meeting, May 29, 2025

High number of new directors

Recent updates

Price target increased by 60% to US$16.00

Insufficient new directors

LeonaBio, Inc., Annual General Meeting, Jun 22, 2026

LeonaBio, Inc. announced that it has received $89.724073 million in funding

Leonabio, Inc. Announces the Appointment of Mark F. Kubik as Chief Business Officer

Athira Pharma, Inc. Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate

New major risk - Share price stability

Athira Pharma, Inc. announced that it expects to receive $89.724073 million in funding

Insufficient new directors

New minor risk - Share price stability

Athira Pharma, Inc., Annual General Meeting, May 29, 2025

New major risk - Market cap size

High number of new directors

Athira Pharma Receives Notification Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Global Select Market

Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases

Price target decreased by 46% to US$4.00

Athira Pharma, Inc. Announces Topline Results from Phase 2/3 Lift-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer's Disease

Athira Pharma Announces Last Patient Completed Lift-Ad Clinical Trial of Fosgonimeton in Mild-To-Moderate Alzheimer’s Disease

New major risk - Financial position

Independent Chairwoman of the Board recently bought US$100k worth of stock

Athira Pharma, Inc. Announces Proposed Settlement of Stockholder Derivative Action

Athira Pharma, Inc. Appoints Javier San Martin, M.D., as Chief Medical Officer

Athira Pharma, Inc. Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's Disease

Athira Pharma, Inc., Annual General Meeting, May 23, 2024

New minor risk - Market cap size

Will Athira Pharma (NASDAQ:ATHA) Spend Its Cash Wisely?

Athira Pharma, Inc. Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)

Athira Pharma, Inc. Announces Hans Moebius Retires as Chief Medical Officer

Price target increased by 23% to US$9.25

Athira Pharma, Inc. Presents Preclinical Data Highlighting Fosgonimeton's Neuroprotective Effects Against Amyloid-B-Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer's Disease

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?

New minor risk - Market cap size

Athira Pharma, Inc. Appoints Andrew Gengos as Chief Financial Officer

Athira Pharma, Inc. Presents Phase 2 Clinical Data Correlating Improvements in Biomarkers of Neurodegeneration and Neuroinflammation with Improvements in Measures of Cognition and Function in Alzheimer’s Disease

CFO & Chief Business Officer recently bought US$192k worth of stock

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?

Athira Pharma, Inc. Announces the Appointment of Andrew Gengos as Chief Business Officer

Athira Pharma, Inc. Announces CFO Changes

Independent Director recently bought US$60k worth of stock

Price target decreased by 33% to US$7.83

Athira Pharma Announces Promotion of Kevin Church to Chief Scientific Officer

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans?

Chief Financial Officer recently bought US$142k worth of stock

Athira Pharma, Inc. Announces Publication of Fosgonimeton Preclinical Results in Neurotherapeutics

Independent Chairwoman of the Board recently bought US$99k worth of stock

Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND

Price target increased to US$11.75

High number of new and inexperienced directors

Athira Pharma Advances Phase 2/3 Lift-Ad Clinical Study of Fosgonimeton in Mild-To Moderate Alzheimer's Patients Following Independent, Unblinded Interim Analysis

Price target increased to US$11.75

Athira Alzheimer's drug trial gets monitoring panel nod to continue after efficacy analysis

Athira Pharma, Inc. Provides Update on Plans for Ongoing LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients

Athira Pharma GAAP EPS of -$0.65

We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely

Athira Pharma Presents Data from ACT-AD Phase 2 Proof-of-Concept Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients at the Alzheimer's Association International Conference 2022

Price target decreased to US$15.40

Athira Pharma, Inc. Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease

Athira Pharma: The Market Is Missing A Potential New Alzheimer's Drug

Athira Pharma, Inc. Announces New Board Appointments

Richard A Kayne Issues Letter to Shareholders of Athira Pharma Inc

Athira Pharma Extends Ongoing Open Label Extension Study for LIFT-AD and ACT-AD Clinical Trials of Fosgonimeton (ATH-1017) for Mild to Moderate Alzheimer’s Disease

Companies Like Athira Pharma (NASDAQ:ATHA) Are In A Position To Invest In Growth

Richard A Kayne Communicates with Athira Pharma Inc

High number of new and inexperienced directors

Richard A. Kayne Files an Investor Presentation to Shareholders of Athira Pharma

Richard A. Kayne Provides Information to Shareholders of Athira Pharma Inc

Athira Pharma, Inc., Annual General Meeting, May 19, 2022

Athira Pharma, Inc. Doses First Subject in Phase 1 Clinical Trial of HGF/MET Positive Modulator, ATH-1020, an Orally Available Small Molecule for Neuropsychiatric Conditions

Independent Chairman of the Board recently bought US$105k worth of stock

マネジメント基準チェック /34